Aldeyra Therapeutics Stock Price - ALDX

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 5.93 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Aldeyra Therapeutics Inc ALDX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.10 -1.66% 5.93 6.18 5.84 6.06 6.03 19:59:37
Bid Price Ask Price Spread Spread % News
5.00 6.60 1.60 24.24% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,011 132,406 $ 5.96 $ 789,773 246,047 3.75 - 12.94
Last Trade Time Type Quantity Stock Price Currency
16:12:24 10 $ 5.95 USD

Aldeyra Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 165.76M 27.95M $ -38.89M -1.80 - 27.10M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Aldeyra Therapeutics News

Latest ALDX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALDX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.456.5195.846.17128,120-0.52-8.06%
1 Month6.646.715.676.14188,028-0.71-10.69%
3 Months5.6410.104.485.79315,3310.295.14%
6 Months5.4510.104.315.64244,1270.488.81%
1 Year8.5312.943.757.45352,788-2.60-30.48%
3 Years5.4516.703.758.52298,3400.488.81%
5 Years9.4416.703.398.40191,491-3.51-37.18%

Aldeyra Therapeutics Description

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Your Recent History
Aldeyra Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200126 10:14:17